Seasonal use, holiday use, and the honest state of the evidence

The word microdosing has migrated into this field from an unrelated context and carries an implication it has not earned: that a small dose produces a distinct and desirable class of effect. For these agents there is no evidence of any such thing. A low dose produces a smaller version of the same effect, with the caveat that the dose-response relationships for weight, for glycaemia and for gastrointestinal tolerability have different shapes, so the ratio of benefit to burden does change across the range. That is worth knowing and it is not what the borrowed word implies.

Intermittent schedules: the evidence, stated in full

This section is short because the evidence is. The Journal has searched the trial registries and the published literature for any randomised comparison of an intermittent schedule against a standard weekly schedule for any GLP-1 receptor agonist or dual agonist, at any dose, for any indication. We have found none. We have also found no observational cohort large enough to characterise outcomes on such a schedule with the standard confounders addressed.

What exists is dose-ranging data from the phase 2 programmes, which establishes that lower average exposures produce smaller weight effects, and pharmacokinetic modelling, which establishes what average exposure and what peak-to-trough ratio a given interval would produce. Neither tells you whether a fortnightly schedule maintains weight in somebody who has already lost it, which is the question actually being asked.

An absence of evidence is not evidence of harm and the Journal does not present it as such. It is, however, the entire evidentiary position, and readers encountering confident protocols for intermittent use should know that the confidence is not coming from data. Nothing in this section is advice, and the compounds sold for research use only that appear in some of these protocols are not approved for human use.

The arithmetic of a fortnightly schedule

For a drug eliminated with first-order kinetics, the accumulation ratio at steady state is approximately one divided by one minus the exponential of minus the elimination rate constant times the dosing interval. For a seven-day half-life given weekly, that yields a ratio of about two. Given fortnightly, the interval is two half-lives, the residual fraction at the next dose is a quarter, and the accumulation ratio falls to about one and a third.

Two consequences follow. Average concentration on a fortnightly schedule at the same nominal dose is roughly a third lower than weekly, not half, because accumulation differs. And the peak-to-trough ratio rises from modest to fourfold, so the exposure pattern is qualitatively different: the person spends part of each cycle at an exposure that would be sub-therapeutic on a weekly schedule and part at a higher peak.

What the arithmetic cannot tell you is whether that pattern is better, worse or equivalent for maintaining weight, because the relationship between exposure pattern and weight effect is not known — only the relationship between average exposure and weight effect at steady state. The modelling is solid and it answers a different question from the one people bring to it.

Resuming after an interruption is a fresh escalation

This is the most practically consequential item in the whole subject and the one least often stated in advance. Gastrointestinal tolerability to these agents develops over weeks of continued exposure and decays when exposure is removed. After four weeks without the drug, plasma concentrations are a small fraction of steady state and the tolerability accommodation has substantially reset. Resuming at the previous maintenance dose therefore presents the system with an exposure step it has not experienced for a month.

The clinical convention — resume at a lower dose and re-escalate — follows from the pharmacokinetics rather than from caution.¹ Product labelling for several agents in the class advises consideration of re-initiation at a lower dose after an extended interruption, and the threshold at which this applies differs between products, which is a detail worth checking against the specific label rather than a general rule.

The shortage period demonstrated the consequence of ignoring this at scale. Large numbers of people lost access for six to ten weeks, resumed where they had left off, and experienced nausea and vomiting considerably worse than during their original escalation. It was predictable, it was predicted by anybody who had read the label carefully, and it was almost never communicated.

What would settle the maintenance question

The Journal’s position is that three trials would resolve almost everything currently argued about in this area, and that all three are straightforward. The first is a dose-reduction design: after a lead-in to target, randomise to full dose, one step down, two steps down, or placebo, and follow for a year with weight as the primary endpoint. It would establish the shape of the descending dose-response curve and would cost a fraction of a pivotal programme.

The second is an interval design: after a lead-in, randomise to weekly, fortnightly and three-weekly administration at the same nominal dose. It would answer the intermittent-schedule question directly and would settle whether the exposure pattern matters independently of average exposure.

The third is a taper design: randomise abrupt cessation against a stepped reduction over twelve weeks, with appetite, eating behaviour and weight measured for a year afterwards. It would test the only argument for tapering that is worth testing.

None of the three is under way as far as the Journal can establish. Readers who know otherwise should write to letters@compoundjournal.com; a registered protocol for any of them would be news in this department.

What this piece is not

This is reporting on a body of trial evidence and it is not advice about whether or how to stop taking a medicine. The decision to discontinue an agent prescribed for glycaemic control, cardiovascular risk or kidney disease is materially different from the decision to discontinue one prescribed for weight, and in every case it belongs with a clinician who has seen the person and knows why the drug was started.

Two further notes. Compounds sold for research use only are not approved for human use in any jurisdiction, and nothing here should be read as guidance about using them or about stopping their use. And where this piece describes what clinicians report doing about maintenance dosing, that is description of practice and not a schedule anybody should adopt from a magazine.

The Journal takes correspondence on this subject at letters@compoundjournal.com and factual challenges at standards@compoundjournal.com. Letters describing a personal experience of stopping are read with attention and are published, where they are published, as accounts rather than as evidence — a distinction this department tries hard to preserve in both directions.

The stopping question has a clear answer and an unclear set of consequences. Treatment maintains weight loss while it continues; stopping abruptly returns most but not all of the lost weight within a year; and nothing in the randomised record supports the claim that a person ends up worse off than they started. What is genuinely unresolved is everything between full dose and nothing, which is where almost every real decision is made.